Dialysis independence following combination daratumumab, thalidomide, bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma with severe renal failure

There is limited data to support the use of daratumumab-containing regimens for patients with multiple myeloma presenting with severe renal failure requiring hemodialysis. We describe a case of successfully achieving dialysis independence with the use of combination daratumumab, bortezomib, thalidomide, cyclophosphamide, and dexamethasone in a patient who had become dialysis-dependent secondary to severe myeloma-induced renal failure. (C) 2020 Elsevier Inc. All rights reserved.